SERUM FERRITIN LEVEL IN CHILDREN WITH β-THALASSEMIA MAJOR: A HOSPITAL BASED PILOT STUDY
DOI:
https://doi.org/10.22159/ijcpr.2026v18i1.58164Keywords:
β-Thalassemia, Ferritin, Iron overload, Blood transfusion, BMIAbstract
Objective: To study the serum ferritin level in children with β-TM patients.
Methods: Clinico-pathological details of β-TM patient’s were entered into a Microsoft Excel and exported to SPSS version 21 (IBM SPSS® software, Chicago, US). P value<0.05 was considered as statistically significant.
Results: Significant correlation between serum ferritin value (P-value 0.001) (mean 1868.67and SD value 1427.68) and number of blood transfusion (mean 67.77 and SD value 66.88) have been observed. Increased number of blood transfusion is associated with increased serum ferritin value (P-value 0.001 and correlation coefficient 0.536**) which represent the iron overload.
Conclusion: Regular monitoring of serum ferritin, and other biochemical parameters will improve the health of β-TM patients. Higher numbers of study samples are needed to validate the result of β-TM patients. Significant correlation has been observed in serum ferritin which shows the iron overload in β-TM patients. Furthermore we need to study on larger sample size for iron overload in β-TM patients.
Downloads
References
1. De Sanctis V, Soliman AT, Elsedfy H, Skordis N, Kattamis C, Angastiniotis M. Growth and endocrine disorders in thalassemia: the international network on endocrine complications in thalassemia (I-CET) position statement and guidelines. Indian J Endocrinol Metab. 2013;17(1):8-18. doi: 10.4103/2230-8210.107808, PMID 23776848.
2. Mohanty D, Colah RB, Gorakshakar AC, Patel RZ, Master DC, Mahanta J. Prevalence of β-thalassemia and other haemoglobinopathies in six cities in India: a multicentre study. J Community Genet. 2013;4(1):33-42. doi: 10.1007/s12687-012-0114-0, PMID 23086467.
3. Kattamis A, Forni GL, Aydinok Y, Viprakasit V. Changing patterns in the epidemiology of β-thalassemia. Eur J Haematol. 2020;105(6):692-703. doi: 10.1111/ejh.13512, PMID 32886826.
4. Baird DC, Batten SH, Sparks SK. Alpha and beta-thalassemia: rapid evidence review. Am Fam Physician. 2022;105(3):272-80. PMID 35289581.
5. Ali S, Mumtaz S, Shakir HA, Khan M, Tahir HM, Mumtaz S. Current status of beta-thalassemia and its treatment strategies. Mol Genet Genomic Med. 2021;9(12):e1788. doi: 10.1002/mgg3.1788, PMID 34738740.
6. Rattananon P, Anurathapan U, Bhukhai K, Hongeng S. The future of gene therapy for transfusion-dependent beta-thalassemia: the power of the lentiviral vector for genetically modified hematopoietic stem cells. Front Pharmacol. 2021;12:730873. doi: 10.3389/fphar.2021.730873, PMID 34658870.
7. Tang CH, Furnback W, Wang BC, Tang J, Tang D, Lu MY. Relationship between transfusion burden healthcare resource utilization and complications in patients with beta-thalassemia in Taiwan: a real-world analysis. Transfusion. 2021;61(10):2906-17. doi: 10.1111/trf.16636, PMID 34505291.
8. De Sanctis V, Soliman AT, Elsedfy H, Soliman NA, Soliman R, El Kholy M. Dysmenorrhea in adolescents and young adults: a review in different country. Acta Biomed. 2016 Jan 16;87(3):233-46. PMID 28112688, PMCID PMC10521891.
9. Baird DC, Batten SH, Sparks SK. Alpha and beta-thalassemia: rapid evidence review. Am Fam Physician. 2022;105(3):272-80. PMID 35289581.
10. Taher AT, Saliba AN. Iron overload in thalassemia: different organs at different rates. Hematology Am Soc Hematol Educ Program. 2017;2017(1):265-71. doi: 10.1182/asheducation-2017.1.265, PMID 29222265.
Published
How to Cite
Issue
Section
Copyright (c) 2026 DIVYA GUPTA
This work is licensed under a Creative Commons Attribution 4.0 International License.